S-1: Carlsmed Files S-1 for IPO, Highlighting AI-Powered Personalized Spine Surgery and Strong Revenue Growth

Sentiment:

Initial Public Offering Registration Statement 26 June 2025 3:30 PM

Carlsmed, Inc., a medical technology company pioneering AI-enabled personalized spine surgery solutions, has filed its S-1 registration statement for an initial public offering, showcasing significant revenue growth and positive clinical outcomes for its aprevo Technology Platform.

Capital raiseThe company is undertaking an Initial Public Offering (IPO) of common stock.Underwriters have a 30-day option to purchase additional shares.Expected net proceeds from the IPO are approximately $X million (midpoint) or $Y million (if overallotment option exercised in full).Historically, the company has raised $105.1 million in aggregate gross equity proceeds since inception through March 31, 2025, primarily from convertible preferred stock sales.Completed Series C convertible preferred stock sales in March 2024, September 2024, and January 2025 for aggregate gross proceeds of $64.5 million.Completed Series B convertible preferred stock sale in April 2022 for aggregate gross proceeds of $30.0 million.The company has $15.6 million in principal outstanding under the Customers Loan Agreement as of March 31, 2025, with an additional $7.5 million currently available for future borrowings and $4.4 million available upon achieving a requisite revenue milestone.

Better than expectedRevenue growth of 100.3% for Q1 2025 compared to Q1 2024, and 97.2% for 2024 compared to 2023, indicates strong commercial adoption.Gross margin improved to 74.9% in Q1 2025 and 73.8% in 2024, demonstrating increasing efficiency.Clinical outcomes from the COMPASS Registry show a significantly lower revision rate (1.5%) for mechanical complications compared to traditional spine fusion (8.7% to 50%), suggesting superior patient outcomes.Recent FDA 510(k) clearance for cervical spine fusion and Breakthrough Device Designation for cervical technology open up a new, large addressable market.Proposed CMS NTAP of up to $21,125 per cervical spine fusion procedure using custom-made devices is a favorable reimbursement development.

Summary

Carlsmed, Inc. is a commercial-stage medical technology company focused on AI-enabled personalized spine surgery solutions, aiming to become the standard of care for spine fusion surgery.
The company's aprevo Technology Platform includes AI-enabled software for 3D planning and visualization, custom-made anatomically designed interbody fusion devices, and post-operative data insights.
The platform is currently marketed for lumbar spine fusion surgery and is being developed for cervical spine fusion surgeries, with commercialization expected in 2026.
Carlsmed reported revenue of $10.2 million for the three months ended March 31, 2025, a 100.3% increase from $5.1 million in the same period of 2024.
Annual revenue for 2024 was $27.2 million, up 97.2% from $13.8 million in 2023.
Gross margin improved to 74.9% in Q1 2025 from 72.0% in Q1 2024, and to 73.8% in 2024 from 71.9% in 2023.
The company incurred net losses of $5.7 million in Q1 2025 and $24.3 million in 2024, with an accumulated deficit of $76.9 million as of March 31, 2025.
The total addressable market for the aprevo Technology Platform in lumbar fusion procedures in the U.S. is estimated at approximately $13.4 billion, based on 445,200 expected surgeries in 2025.
Approximately 372,600 cervical fusion procedures are expected in the U.S. in 2025, representing a significant expansion opportunity.
As of March 31, 2025, 177 surgeon users had completed one or more procedures using the aprevo Technology Platform, up from 103 as of March 31, 2024.
The company's COMPASS Registry interim data for 67 ASD patients showed a 1.5% revision rate for mechanical complications at one-year follow-up, compared to 8.7% to 50% reported for traditional spine fusions.
Carlsmed holds 33 issued patents and approximately 117 pending patent applications, along with various trademarks and trade secrets.
The company has used approximately four million radiographic images to train its AI models, analyzed over one million images from patients using the platform, and created over 40,000 digital twin 3D models of patient anatomies.
The IPO proceeds, along with existing cash and expected cash from sales, are anticipated to fund operating expenses and capital expenditure requirements for at least the next 12 months.

Sentiment

Score: 8

Explanation: Carlsmed demonstrates strong operational momentum with impressive revenue growth and improving gross margins, driven by its innovative AI-enabled personalized spine surgery platform. The positive clinical outcomes, particularly the significantly lower revision rates compared to traditional methods, address a critical unmet need in the market. Recent FDA clearances for cervical fusion and favorable proposed reimbursement codes further expand its market potential. While the company is still operating at a net loss, the IPO proceeds are expected to provide substantial capital for commercial expansion and R&D, supporting its path to profitability. The robust intellectual property and data moat also provide a strong competitive advantage. The primary concerns are the continued net losses and the inherent risks of operating in a highly competitive, regulated industry with reliance on third-party manufacturers and evolving AI technologies.

Positives

Demonstrated strong revenue growth, with a 100.3% period-over-period increase in Q1 2025 and a 97.2% year-over-year increase in 2024.
Achieved improving gross margins, reaching 74.9% in Q1 2025 and 73.8% in 2024.
Received FDA 510(k) clearance for aprevo interbody implants for cervical interbody fusion surgeries in November 2024, following a Breakthrough Device Designation.
CMS announced proposed X-codes in April 2025 for custom-made anatomically designed fusion devices for cervical spine fusion surgeries, potentially offering NTAP of up to $21,125 per procedure.
Clinical data from the COMPASS Registry shows a low revision rate of 1.5% for mechanical complications in ASD patients at one-year follow-up, significantly lower than reported rates for traditional spine fusions (8.7% to 50%).
The aprevo Technology Platform has shown favorable results in achieving post-operative alignment, improving disc space biomechanics, and reducing the need for revision surgery.
The company operates an asset-light business model with on-demand manufacturing of patient-specific implants, leading to attractive gross margins and reduced inventory burden.
Possesses a robust intellectual property portfolio with 33 issued patents and approximately 117 pending patent applications, covering implants, manufacturing, design, software, and AI algorithms.
Has a comprehensive data moat, utilizing millions of radiographic images to train and improve AI models, enhancing personalized surgical planning.

Negatives

Continues to incur substantial net losses, with a net loss of $5.7 million in Q1 2025 and $24.3 million in 2024, and an accumulated deficit of $76.9 million as of March 31, 2025.
Depends entirely on sales of aprevo interbody implants for revenue, posing a concentration risk.
Has a limited operating history and expects to incur additional substantial losses in the foreseeable future as it scales operations.
Relies on a limited number of contract manufacturing organizations (CMOs) for product manufacturing, sterilization, and distribution, increasing supply chain risk.
The successful commercialization of the aprevo Technology Platform for cervical spine fusion surgeries is contingent on obtaining necessary additional FDA clearances, which are not guaranteed on the expected timeline or at all.
Operates in a highly competitive industry with larger, more established competitors who may have greater resources and market share.
Subject to risks associated with the use and development of AI models, including potential for incorrect design, reliance on inadequate data, and unforeseen defects.
Product liability claims and potential recalls could result in substantial costs, reputational harm, and decreased demand.
The continued commercialization and adoption of the platform depend on third-party payor coverage and adequate reimbursement levels, which are subject to change and uncertainty.

Risks

Dependence entirely on sales of aprevo interbody implants for revenue, with potential harm if market acceptance and adoption are not substantial.
Limited operating history and periods of significant business changes, making future prospects difficult to evaluate and requiring effective business management.
History of net losses and expectation to incur additional substantial losses in the foreseeable future.
Business and growth strategy depend on the ability to launch the aprevo Technology Platform for cervical spine fusion surgeries, with no guarantee of timely FDA clearance or commercialization.
Managing the on-demand, customized implant model is expensive, time-consuming, and subject to significant uncertainties, potentially leading to delays or use of competitor products.
Reliance on a limited number of contract manufacturing organizations (CMOs) increases the risk of insufficient quantities, unacceptable costs, and reduced control over the manufacturing process.
Failure of third parties assisting with premarket development activities for future products could delay or prevent regulatory clearance/approval and commercialization.
Operation in a highly competitive industry, with competitive pressures or new developments by competitors potentially rendering the aprevo Technology Platform non-competitive or obsolete.
Future sales in international markets will subject the company to additional costs and risks.
Inability to successfully develop new products and effectively manage their introduction or improve existing products could adversely affect the business.
Exposure to product and other liability claims that could require substantial payments.
Risk of off-label use of aprevo interbody implants harming reputation or resulting in fines/sanctions.
Potential for product recalls, either voluntary or mandated by regulatory authorities, or discovery of serious safety issues.
Unforeseen adverse events or undesirable side effects with products or technologies could lead to market removal or sales limitations.
The size and expected growth of the total addressable market may be smaller than estimated.
Discovery of alternative technologies or other personalized spinal implant technologies could materially adversely affect the business.
Quarterly and annual results may fluctuate significantly and may not fully reflect underlying business performance.
Macroeconomic conditions (inflation, interest rates, geopolitical instability) could materially adversely affect the business.
Extensive government regulation and oversight in the U.S., with failure to comply potentially harming the business.
Failure to maintain marketing authorizations or timely obtain necessary authorizations for future products.
Ongoing regulatory review and scrutiny, with failure to comply with post-marketing requirements leading to enforcement actions.
Products must be manufactured in accordance with applicable laws and regulations (e.g., QSR, QMSR), with non-compliance leading to recalls or production termination.
Risks related to obtaining necessary foreign marketing authorizations for international expansion.
Failure to comply with the Foreign Corrupt Practices Act (FCPA), economic and trade sanctions regulations, and similar laws.
Actual or perceived failures to comply with applicable data privacy and security laws, regulations, standards, and other requirements could adversely affect the business.
Risks associated with the use and development of AI models, including incorrect design, reliance on poor quality data, and regulatory uncertainty.
Information technology system failures, cyberattacks, or cybersecurity deficiencies could disrupt operations and compromise confidential information.
Ability to obtain, maintain, enforce, and protect intellectual property rights is crucial for success.
Potential for claims challenging inventorship or ownership of patents and other intellectual property rights.
Dependence on certain in-licensed intellectual property rights, with risks of license termination or inability to obtain necessary future licenses.
Inability to protect the disclosure and use of confidential information and trade secrets could harm competitive position.
Inadequate protection of trademarks and trade names could hinder brand recognition.
Use of third-party open-source software components carries risks of non-compliance with licenses.
Ability to use net operating loss carryforwards (NOLs) and other tax attributes may be limited due to ownership changes.
Effective tax rate may vary significantly from period to period.
Changes in tax laws or tax rulings could adversely affect effective tax rates and financial condition.
Increased tax burden could result from ongoing or future tax audits.
Terms of the Customers Loan Agreement require meeting certain operating and financial covenants, placing restrictions on flexibility.
Cash deposits with financial institutions exceed insured limits, posing risk in case of bank failure.
Absence of an active trading market for common stock post-IPO may cause price discounts and difficulty in selling shares.
Reduced reporting requirements as an emerging growth company and smaller reporting company may make common stock less attractive to investors.
Increased costs and additional regulations as a public company could lower profits or make business more difficult.
Inability to design, implement, and maintain effective internal control over financial reporting could lead to loss of investor confidence.
No intention to pay dividends in the foreseeable future, meaning return on investment depends on stock price appreciation.
Operating and financial performance not meeting public guidance could cause stock price decline.
Broad discretion in the use of net proceeds from the offering, which may not be used effectively.
Future sales and issuances of securities may cause dilution or decrease stock price.
Principal stockholders and management own a significant percentage of stock, exerting significant control over stockholder approval matters.
Provisions in charter documents and Delaware law could discourage takeovers and lead to management entrenchment.
Claims for indemnification by directors, officers, and agents may reduce available funds.
Exclusive forum provision in amended and restated certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

Carlsmed plans to continue driving adoption and market share for its aprevo Technology Platform in lumbar fusion surgeries. The company expects to commercialize the aprevo Technology Platform for cervical fusion surgery in 2026, contingent on obtaining necessary additional FDA clearances for its cervical software platform and personalized plating solutions. It will invest in further growing its clinical evidence base, including the COMPASS Registry, and continue research and development initiatives to introduce enhancements, new capabilities, and potentially expand into additional spinal indications like cervical corpectomy and cervical disc arthroplasty, and other musculoskeletal applications. The company also intends to engage in market access initiatives for strategic international regions, though no definitive timeline is set.

Management Comments

Michael Cordonnier, Chairman, Chief Executive Officer, President, and Co-Founder, leads the company's strategic direction.
Leonard Greenstein serves as Chief Financial Officer and Treasurer, overseeing financial operations.
William Scott Durall, Chief Commercial Officer, is responsible for commercial strategy and sales.
Niall Casey, Co-Founder and Chief Intellectual Property Officer, manages the company's extensive IP portfolio.
Management believes the unique and differentiated benefits of the aprevo Technology Platform have driven strong adoption since commercial launch.
The company is committed to building upon its strong foundation of clinical evidence demonstrating the efficacy of the aprevo Technology Platform.
Management believes the proposed CMS X-codes for cervical spine fusion will be critical to the commercial success of cervical implants.
Management believes the asset-light business model and streamlined digital production system will drive revenue and enable the path to profitability.

Industry Context

Carlsmed operates in the highly competitive medical device industry, specifically targeting the spine fusion market. The company positions its AI-enabled personalized spine surgery platform as a solution to address significant limitations of traditional spine fusion, such as reliance on 2D imaging, poor fit of stock implants, complicated workflows, and lack of post-operative feedback. These limitations contribute to high rates of malalignment, complications, and revision surgeries, imposing a substantial economic burden on the healthcare system. Carlsmed aims to disrupt this established market by offering patient-specific solutions designed to improve outcomes and reduce costs, seeking to become the new standard of care.

Comparison to Industry Standards

aprevo Technology Platform's interim data from the COMPASS Registry showed a 1.5% revision rate for mechanical complications in ASD patients at one-year follow-up, which compares favorably to published rates for traditional spine fusions ranging from 8.7% to 50% over similar periods.
In a study of 217 patients, 82% of lumbar levels treated with aprevo interbody implants achieved intervertebral lordosis (IVL) alignment within 5 degrees of target, and 97% within 10 degrees, suggesting more predictable alignment compared to traditional methods where no significant differences in gained lordosis were found between various stock interbody devices.
A study of 72 DDD patients showed 45% of those with low distal lumbar lordosis (DLL) were restored to a normal range using aprevo implants, a statistically significant increase compared to only 10% in a separate study using stock implants.
Hypolordotic DDD patients treated with aprevo interbody implants showed statistically significant improvement in Lordosis Distribution Index (LDI), trending towards the normal range, whereas a comparable study with stock implants showed hypolordotic patients tending to worsen.
A multicenter study of 65 ASD patients using aprevo interbody implants achieved targeted PI-LL within 5 degrees in 44.6% of patients and missed by greater than 15 degrees in only 15.3%, significantly outperforming a traditional ISSG cohort (31.5% and 30.8% respectively).
Post-operative CT imaging of 15 patients (24 aprevo implants) showed an implant-endplate contact area ratio of 93.9%, 95.8% free of subsidence, and 100% fusion visible, suggesting improved biomechanics compared to traditional methods where subsidence occurs in 13% to 27% of patients.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Commercial Officer	William Scott Durall (SVP, Marketing)	William Scott Durall	December 2024	Promotion from Senior Vice President, Marketing.
Director	N/A	Kevin OBoyle	September 2024	Appointment to the Board of Directors.
Various Executive Roles	N/A	Michael Cordonnier, Leonard Greenstein, William Scott Durall, Niall Casey	June 24, 2025	New employment agreements superseding prior offer letters/agreements.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Bylaws Amendment	Amended and Restated Bylaws to be effective immediately prior to the completion of this offering, outlining corporate offices, stockholder meetings, director powers, committees, officers, capital stock, and general matters.	Immediately prior to IPO completion	Establishes detailed rules for corporate operations, including meeting procedures, voting rights, and director responsibilities.
Certificate of Incorporation Amendment	Amended and Restated Certificate of Incorporation to be effective immediately prior to the completion of this offering, setting authorized capital stock, director classification, and anti-takeover provisions.	Immediately prior to IPO completion	Defines the company's capital structure, implements a classified board, and includes provisions that may discourage unsolicited acquisition proposals.
Board Structure	Board of Directors will be classified into three staggered classes (Class I, Class II, Class III) with three-year terms.	Immediately prior to IPO completion	May delay or prevent stockholder efforts to effect a change of management or control, enhancing board stability.
Director Removal	Directors may only be removed for cause by the affirmative vote of at least 66 2/3% of the voting power of all then-outstanding shares of voting stock.	Immediately prior to IPO completion	Increases the difficulty for stockholders to remove directors without cause, potentially entrenching current management.
Board Vacancy Filling	Vacancies on the Board, including newly created directorships, may only be filled by the affirmative vote of a majority of directors then in office, not by stockholders, subject to preferred stock rights.	Immediately prior to IPO completion	Centralizes control over board composition with the existing board, potentially limiting stockholder influence.
Stockholder Action Method	Any action to be taken by stockholders must be effected at a duly called annual or special meeting and cannot be taken by written consent or electronic transmission.	Immediately prior to IPO completion	Limits stockholders' ability to act quickly without a formal meeting, potentially hindering activist investors.
Special Meeting Calling	Special meetings of stockholders may only be called by the Board of Directors, not by stockholders.	Immediately prior to IPO completion	Restricts stockholders' ability to convene meetings to address urgent matters or propose changes.
Stockholder Proposal/Nomination Procedures	Stockholders seeking to present proposals or nominate candidates for election as directors must provide advance written notice with specific requirements regarding form and content.	Immediately prior to IPO completion	Establishes formal procedures for stockholder engagement, potentially making it more challenging for unsolicited proposals.
Cumulative Voting	Does not provide for cumulative voting rights, allowing holders of a majority of voting shares to elect all directors.	Immediately prior to IPO completion	Favors majority shareholders in director elections, potentially limiting minority shareholder representation.
Code of Business Conduct and Ethics	Adoption of a Code of Business Conduct and Ethics applicable to all employees, officers, agents, and representatives.	Upon effectiveness of registration statement	Establishes ethical guidelines and compliance standards for the company's operations.
Board Committees	Establishment of an audit committee, a compensation committee, and a nomination and corporate governance committee, each operating under a charter.	Upon effectiveness of registration statement	Enhances corporate oversight and compliance with Nasdaq listing rules and Sarbanes-Oxley Act requirements.
Lead Independent Director	Kevin Sidow will be appointed as the lead independent director.	Upon effectiveness of registration statement	Provides a designated leader for independent directors, enhancing independent oversight of management.
Incentive Compensation Recovery Policy	Adoption of an incentive compensation recovery policy (clawback policy) compliant with Nasdaq listing rules.	In connection with IPO	Allows the company to recoup incentive-based compensation in certain circumstances, aligning with regulatory requirements and promoting accountability.
Non-Employee Director Compensation Policy	Adoption of a non-employee director compensation program, including cash retainers and RSU awards.	Upon effectiveness of registration statement	Formalizes compensation for independent directors, aiming to attract and retain qualified individuals.

Legal Proceedings

The company is not presently a party to any litigation the outcome of which, if determined adversely, would materially and adversely affect its business, financial condition, or results of operations.
The company may become subject to legal disputes and regulatory proceedings in the future related to product liability, intellectual property infringement, employment matters, and other applicable laws.

Related Party Transactions

In March, September 2024, and January 2025, entities affiliated with B Capital Group purchased $43,999,998.33 of Series C convertible preferred stock, and entities affiliated with U.S. Venture Partners purchased $17,999,997.41 of Series C convertible preferred stock.
In April 2022, entities affiliated with B Capital Group purchased $19,999,998.50 of Series B convertible preferred stock, and entities affiliated with U.S. Venture Partners purchased $5,999,998.32 of Series B convertible preferred stock.
Michael Cordonnier (CEO, Director), Niall Casey (Chief IP Officer, Director), Kevin Sidow (Director), and Philip Young (Director) also purchased Series B convertible preferred stock in April 2022.
The company is party to an amended and restated investor rights agreement with certain holders of its convertible preferred stock and common stock, including affiliates of executive officers and directors, which grants certain registration rights.
The amended and restated voting agreement and the amended and restated right of first refusal and co-sale agreement, involving certain related parties, will terminate upon the completion of this offering.
New employment agreements were entered into with Michael Cordonnier, Leonard Greenstein, William Scott Durall, and Niall Casey, effective June 24, 2025, superseding prior agreements and outlining compensation and severance terms.
The company will enter into indemnification agreements with each of its executive officers and directors prior to the IPO closing.

Stakeholder Impact

Shareholders: Will experience immediate and substantial dilution from the IPO. Existing principal stockholders and management will retain significant control post-IPO. Future equity raises and equity incentive plans may cause further dilution. Investment return will depend on stock price appreciation as no dividends are planned.
Employees: Benefit from equity incentive plans (2019 Plan, 2025 Plan, 2025 ESPP) designed to attract, retain, and motivate. New employment agreements for executives provide defined compensation and severance benefits.
Customers (Hospitals and Surgeons): Benefit from the aprevo Technology Platform's potential for improved patient outcomes, reduced revision surgeries, and seamless integration into existing surgical workflows. The on-demand inventory model eliminates burdensome inventory management for hospitals. Favorable reimbursement codes (MS-DRGs and proposed NTAP) support adoption.
Healthcare System: The aprevo Technology Platform aims to reduce the significant economic burden associated with revision spine surgeries, which frequently exceed $100,000 in direct and indirect costs.
Regulatory Bodies: The company is subject to extensive U.S. and potentially foreign regulations, including FDA clearances and compliance with healthcare fraud and abuse laws. Compliance efforts are ongoing and critical to operations.

Next Steps

Continue to drive adoption and market share capture for aprevo in lumbar fusion surgeries.
Launch the aprevo Technology Platform for cervical spine fusion surgeries in 2026, assuming necessary additional FDA clearances for cervical software platform and personalized plating solutions.
Invest in further growing the base of clinical evidence, including the anticipated final data release for the COMPASS Registry in early 2027.
Continue to develop research and development initiatives, including predictive analytic models and expansion into additional spinal indications (e.g., cervical corpectomy, cervical disc arthroplasty) and other musculoskeletal applications.
Engage in market access initiatives for strategic international regions, with planning in early stages and no definitive timeline.

Key Dates

Date	Description
2018-06-04	Company incorporated in Delaware.
2019-09-17	Carlsmed, Inc. Stock Incentive Plan (2019 Plan) adopted by the Board of Directors.
2020-04-24	2019 Stock Incentive Plan amended.
2020-12-15	Indemnification Agreement template date.
2020-12-20	FDA 510(k) clearance for aprevo interbody implants for correction of adult lumbar spinal deformity (ASD); Loan and Security Agreement entered with Signature Bank.
2021-02-01	First U.S. patient implant using aprevo Technology Platform.
2021-04-30	Common Stock Warrant issued in connection with SVB Loan.
2021-05-01	Carlsbad office lease commenced.
2021-07-01	Common Stock Warrant became exercisable for additional shares.
2021-10-01	CMS awarded NTAP for aprevo lumbar procedures; U.S. commercial launch of aprevo Technology Platform for lumbar spine fusion surgery.
2022-02-01	SVB Loan amended to draw additional principal.
2022-04-18	Sale of Series B convertible preferred stock completed; 2019 Stock Incentive Plan amended.
2022-08-01	FDA 510(k) clearance for aprevo Technology Platform for treatment of degenerative disc disease (DDD) of the lumbar spine.
2022-12-01	SVB Loan Agreement terminated and repaid in full.
2023-03-21	First Amendment to Loan and Security Agreement with Signature Bridge Bank, N.A.
2023-08-02	Leonard Greenstein's original employment agreement date.
2023-08-03	Leonard Greenstein's Employee Proprietary Information and Invention Assignment Agreement (PIIA) date.
2023-08-01	Leonard Greenstein became Chief Financial Officer and Treasurer.
2023-09-01	FDA granted second Breakthrough Device Designation for cervical technology.
2023-10-02	Customers Loan Agreement amended to formally document Customers Bank as successor lender; $3.1 million drawn under Customers Loan Agreement.
2023-12-04	Carlsbad Lease modified, extending term to July 1, 2028.
2024-03-07	Third Amendment to Customers Loan Agreement; Series B Warrant issued.
2024-03-12	Amended and Restated Investors Rights Agreement and Amended and Restated Voting Agreement date.
2024-05-01	$6.3 million drawn under Customers Loan Agreement.
2024-09-01	William Scott Durall commenced services as Senior Vice President, Marketing.
2024-09-01	Kevin OBoyle became a member of the Board of Directors.
2024-10-01	CMS established new MS-DRG codes for custom-made anatomically designed devices.
2024-11-01	FDA 510(k) clearance for aprevo interbody implants for cervical interbody fusion surgeries.
2024-12-01	William Scott Durall became Chief Commercial Officer.
2024-12-30	Fourth Amendment to Customers Loan Agreement; Series C Warrant issued.
2025-01-01	Series C convertible preferred stock issued ($12.0 million gross proceeds); 2019 Stock Incentive Plan amended.
2025-03-05	Performance and market-based vesting RSU grant to Michael Cordonnier.
2025-04-01	CMS announced proposed ICD-10-PCS (X-codes) for the use of custom-made anatomically designed fusion devices for cervical spine fusion surgeries.
2025-06-24	New employment agreements for Michael Cordonnier, Leonard Greenstein, William Scott Durall, and Niall Casey became effective.
2025-06-26	S-1 Registration Statement filed with the SEC.
2025-10-01	Proposed effective date for NTAP of up to $21,125 per cervical spine fusion procedure.
2026-01-01	Expected commercialization of the aprevo Technology Platform for cervical fusion surgery.
2027-01-01	Anticipated final data release for the COMPASS Registry.
2028-07-01	Carlsbad office lease expiration.
2029-10-31	Customers Loan Agreement maturity date.
2034-12-30	Series B and Series C Warrants expiration date.
2037-01-01	Earliest expected expiration date for issued patents.
2044-12-31	Latest expected expiration date for issued patents.

Recommendation

strong buy

Carlsmed presents a compelling investment opportunity due to its innovative AI-enabled personalized spine surgery platform, which addresses a large and underserved market with significant unmet clinical needs. The company has demonstrated exceptional revenue growth (100%+ year-over-year) and improving gross margins, indicating strong market adoption and operational efficiency. Positive interim clinical data from the COMPASS Registry, showing significantly lower revision rates compared to traditional methods, provides a strong competitive differentiator and validates the platform's value proposition. Recent FDA clearances for cervical spine fusion and the prospect of premium reimbursement (NTAP) for these procedures unlock substantial future growth avenues. While the company is currently unprofitable, the IPO proceeds are expected to provide ample capital to fuel commercial expansion, R&D, and ultimately drive towards profitability. The robust intellectual property portfolio and growing data moat further solidify its competitive position. The risks associated with a limited operating history, reliance on CMOs, and regulatory complexities are noted, but the disruptive potential and demonstrated early success of the technology outweigh these concerns for a seasoned investor.

Keywords

IPO, S-1, Carlsmed, aprevo, spine surgery, AI-enabled, personalized medicine, medical device, interbody fusion, lumbar fusion, cervical fusion, Degenerative Disc Disease, Adult Spinal Deformity, FDA clearance, Breakthrough Device Designation, CMS reimbursement, NTAP, 3D planning, patient-specific implants, orthopedic, medical technology, biomedical

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.